promo_leaderboard Ad
‹ All stocks
SUPN

Supernus Pharmaceuticals

SUPN · NASDAQ · Healthcare
$29.25
▲ $0.42 (1.46%)
$28.80 $28.95 $29.10 $29.25 $29.25 21:34 15:04
Day range
$28.46 – $29.28
Year range
$25.92 – $59.68
Open
$28.72
Previous close
$28.83
Market cap
$6.08B
Volume (24h)
$144.9K
Volume (52w)
$4.24M
Performance
7D
▲ 1.74%
1M
▼ -26.58%
3M
▼ -39.74%
6M
▼ -40.77%
1Y
▼ -35.13%
YTD
▼ -40.87%
3Y
▲ 7.10%
5Y
▼ -10.96%
All-time
▲ 444.69%
Key statistics
P/E ratio
8.68
EPS (TTM)
$3.37
Dividend yield
27.79%
Dividend (TTM)
$8.13
Payout ratio
241.25%
Shares outstanding
207.7M
About Supernus Pharmaceuticals

Supernus Pharmaceuticals, Inc. is a biopharmaceutical firm dedicated to developing and marketing therapies for central nervous system (CNS) disorders within the United States. Its portfolio of marketed products includes Trokendi XR, an extended-release topiramate formulation prescribed for both epilepsy management and migraine prevention. Another key product is Oxtellar XR, an extended-release oxcarbazepine designed for the standalone treatment of partial-onset epileptic seizures in patients aged 6 to 17 and adults. The company also offers Qelbree, a selective norepinephrine reuptake inhibitor approved for attention-deficit hyperactivity disorder (ADHD) in children and adolescents aged 6 to 17. For advanced Parkinson's Disease (PD) patients, APOKYN offers acute, intermittent relief during "off" episodes of hypomobility, and XADAGO serves as an adjunctive treatment with levodopa/carbidopa for those experiencing similar off periods. Other offerings include GOCOVRI, which targets dyskinesia in PD patients, and Osmolex ER, used for Parkinson's disease and drug-induced extrapyramidal reactions in adults. MYOBLOC, a Type B toxin, is indicated for cervical dystonia and sialorrhea in adults. Beyond its commercial portfolio, Supernus is actively developing several investigational therapies. These include Qelbree (SPN-812), which has successfully completed Phase III trials for ADHD. SPN-830, a late-stage drug/device combination, aims to prevent off episodes in PD patients. SPN-817 is a novel compound in Phase I trials for severe epilepsy. SPN-820 is undergoing Phase II trials for resistant depression, and SPN-443 and SPN-446 are in earlier, preclinical stages for various CNS indications. Products are distributed through a network of pharmaceutical wholesalers, specialty pharmacies, and authorized distributors. Established in 2005, Supernus Pharmaceuticals is headquartered in Rockville, Maryland.

Visit website
Country: United States of America
More in Healthcare